Lantidra, the first allogeneic pancreatic islet cellular therapy for type 1 diabetes

      Lantidra is the first allogeneic (donor) pancreatic islet cellular therapy, derived from deceased donor pancreatic cells, for treating type 1 diabetes. Approved by the U.S. FDA, Lantidra offers a new treatment option for adults with type 1 diabetes who struggle to achieve target glycated hemoglobin levels due to recurrent episodes of severe hypoglycemia, despite intensive diabetes management and education. The primary mechanism of action for Lantidra is believed to be insulin secretion by the infused allogeneic islet beta cells. For some patients with type 1 diabetes, these infused cells can produce sufficient insulin, eliminating the need for insulin injections or pumps to manage their blood sugar levels. Lantidra is administered via a single infusion into the hepatic portal vein.

Simplera – A breakthrough innovation from Medtronic

      Simplera, Medtronic's latest Continuous Glucose Monitoring (CGM) system, is designed for individuals with diabetes aged 2 years and older. This device represents a significant upgrade from the Guardian 4 sensor, featuring a compact, disposable design that eliminates the need for fingersticks. As Medtronic’s first fully disposable CGM, Simplera integrates the sensor and transmitter into a single unit. It simplifies the insertion process with a streamlined two-step method, minimizing the potential for errors. Approved in Europe, Simplera is compatible with Apple iOS and Android devices and offers notifications on the Apple Watch. When used with the InPen, it forms part of Medtronic’s Smart MDI system. The integration of Simplera with Medtronic’s MiniMed 780G AID system is under regulatory review in Europe. The CGM has a two-hour warm-up time and a seven-day lifespan.